Chronic (-)-epicatechin improves vascular oxidative and inflammatory status but not hypertension in chronic nitric oxide-deficient rats

British Journal of Nutrition

Volumn 106, Issue 9, 2011, Pages 1337-1348

  Gómez Guzmán, Manuel ^a   Jiménez, Rosario ^a   Sánchez, Manuel ^a   Romero, Miguel ^a   O'Valle, Francisco ^b   Lopez Sepulveda, Rocío ^a   Quintela, Ana María ^a   Galindo, Pilar ^a   Zarzuelo, María José ^a   Bailón, Elvira ^a   Delpón, Eva ^c   Perez Vizcaino, Francisco ^c,d   Duarte, Juan ^a  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

( ) Epicatechin; Hypertension; Inflammation; N G nitro l arginine methyl ester; Superoxide

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; CYCLOOXYGENASE 2; DRINKING WATER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPICATECHIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; METHYLCELLULOSE; MITOGEN ACTIVATED PROTEIN KINASE 1; N(G) NITROARGININE METHYL ESTER; NITROUS OXIDE; PROSTANOID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; ENZYME PHOSPHORYLATION; HEART RATE; HEART VENTRICLE HYPERTROPHY; KIDNEY PARENCHYMA; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE; UPREGULATION; VASOCONSTRICTION;

ANIMALS; ATHEROSCLEROSIS; BLOOD PRESSURE; CATECHIN; CYCLOOXYGENASE 2; ENDOTHELIUM, VASCULAR; HYPERTENSION; HYPERTROPHY; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY; MALE; MAP KINASE SIGNALING SYSTEM; MYOCARDIUM; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PHOSPHORYLATION; PHYTOTHERAPY; PLANT EXTRACTS; PROSTAGLANDINS; PROTEINURIA; RATS; RATS, WISTAR; UP-REGULATION; VASCULAR DISEASES; VASOCONSTRICTION;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 80055058069     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114511004314     Document Type: Article

References (40)

1. Duffy SJ, Keaney JF Jr, Holbrook M, et al. (2001) Short-and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 104, 151-156. (Pubitemid 32655830)
2. Buijsse B, Feskens EJ, Kok FJ, et al. (2006) Cocoa intake, blood pressure, and cardiovascular mortality: the Zutphen Elderly Study. Arch Intern Med 166, 411-417.
3. Ding EL, Hutfless SM, Ding X, et al. (2006) Chocolate and prevention of cardiovascular disease: a systematic review. Nutr Metab (Lond) 3, 2.
4. Nagao T, Hase T & Tokimitsu I (2007) A green tea extract high in catechins reduces body fat and cardiovascular risks in humans. Obesity (Silver Spring) 15, 1473-1483. (Pubitemid 47110911)
5. Deka A & Vita JA (2011) Tea and cardiovascular disease. Pharmacol Res 64, 136-145.
6. Fisher ND, Hughes M, Gerhard-Herman M, et al. (2003) Flavanol-rich cocoa induces nitric-oxide-dependent vasodi-lation in healthy humans. J Hypertens 21, 2281-2286. (Pubitemid 38293567)
7. Hirata K, Shimada K, Watanabe H, et al. (2004) Black tea increases coronary flow velocity reserve in healthy male subjects. Am J Cardiol 93, 1384-1388, A1386. (Pubitemid 38692466)
8. Schroeter H, Heiss C, Balzer J, et al. (2006) (2)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci USA 103, 1024-1029. (Pubitemid 43212215)
9. Taubert D, Berkels R, Roesen R, et al. (2003) Chocolate and blood pressure in elderly individuals with isolated systolic hypertension. JAMA 290, 1029-1030. (Pubitemid 37430441)
10. Matsuyama T, Tanaka Y, Kamimaki I, et al. (2008) Catechin safely improved higher levels of fatness, blood pressure, and cholesterol in children. Obesity (Silver Spring) 16, 1338-1348. (Pubitemid 351770536)
11. Grassi D, Lippi C, Necozione S, et al. (2005) Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr 81, 611-614.
12. Holt RR, Lazarus SA, Sullards MC, et al. (2002) Procya-nidin dimer B2 [epicatechin-(4beta-8)-epicatechin] in human plasma after the consumption of a flavanol-rich cocoa. Am J Clin Nutr 76, 798-804.
13. Keen CL, Holt RR, Oteiza PI, et al. (2005) Cocoa antioxidants and cardiovascular health. Am J Clin Nutr 81, 298S-303S.
14. Duarte J, Perez Vizcaino F, Utrilla P, et al. (1993) Vasodilatory effects of flavonoids in rat aortic smooth muscle. Structure-activity relationships. Gen Pharmacol 24, 857-862. (Pubitemid 23231766)
15. Huang Y, Zhang A, Lau CW, et al. (1998) Vasorelaxant effects of purified green tea epicatechin derivatives in rat mesenteric artery. Life Sci 63, 275-283. (Pubitemid 28302470)
16. Ihm SH, Lee JO, Kim SJ, et al. (2009) Catechin prevents endothelial dysfunction in the prediabetic stage of OLETF rats by reducing vascular NADPH oxidase activity and expression. Atherosclerosis 206, 47-53.
17. Ramirez-Sanchez I, Maya L, Ceballos G, et al. (2010) (2)-Epicatechin activation of endothelial cell endothelial nitric oxide synthase, nitric oxide, and related signaling pathways. Hypertension 55, 1398-1405.
18. Steffen Y, Gruber C, Schewe T, et al. (2008) Mono-O-methylated flavanols and other flavonoids as inhibitors of endothelial NADPH oxidase. Arch Biochem Biophys 469, 209-219. (Pubitemid 50008450)
19. Luvara G, Pueyo ME, Philippe M, et al. (1998) Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II antagonism. Arterioscler Thromb Vasc Biol 18, 1408-1416. (Pubitemid 28421878)
20. Zatz R & Baylis C (1998) Chronic nitric oxide inhibition model six years on. Hypertension 32, 958-964. (Pubitemid 29001420)
21. Duarte J, Perez-Palencia R, Vargas F, et al. (2001) Antihyper-tensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Br J Pharmacol 133, 117-124. (Pubitemid 32500458)
22. Esterbauer H & Cheeseman KH (1990) Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 186, 407-421. (Pubitemid 20279982)
23. Duarte J, Ocete MA, Perez-Vizcaino F, et al. (1997) Effect of tyrosine kinase and tyrosine phosphatase inhibitors on aortic contraction and induction of nitric oxide synthase. Eur J Pharmacol 338, 25-33. (Pubitemid 27479073)
24. Vera R, Sanchez M, Galisteo M, et al. (2007) Chronic administration of genistein improves endothelial dysfunction in spontaneously hypertensive rats: involvement of eNOS, caveolin and calmodulin expression and NADPH oxidase activity. Clin Sci (Lond) 112, 183-191.
25. Sanchez M, Lodi F, Vera R, et al. (2007) Quercetin and isorhamnetin prevent endothelial dysfunction, superoxide production, and overexpression of p47phox induced by angiotensin II in rat aorta. J Nutr 137, 910-915. (Pubitemid 46596886)
26. Piskula MK & Terao J (1998) Accumulation of (2)-epicate-chin metabolites in rat plasma after oral administration and distribution of conjugation enzymes in rat tissues. J Nutr 128, 1172-1178. (Pubitemid 28317683)
27. Bartunek J, Weinberg EO, Tajima M, et al. (2000) Chronic N(G)-nitro-L-arginine methyl ester-induced hypertension: novel molecular adaptation to systolic load in absence of hypertrophy. Circulation 101, 423-429. (Pubitemid 30067400)
28. Li JM, Gall NP, Grieve DJ, et al. (2002) Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40, 477-484.
29. Vaziri ND (2004) Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 13, 93-99. (Pubitemid 39069904)
30. Zhen J, Lu H, Wang XQ, et al. (2008) Upregulation of endothelial and inducible nitric oxide synthase expression by reactive oxygen species. Am J Hypertens 21, 28-34.
31. Auch-Schwelk W, Katusic ZS & Vanhoutte PM (1990) Thromboxane A2 receptor antagonists inhibit endothelium-dependent contractions. Hypertension 15, 699-703. (Pubitemid 20189444)
32. Duarte J, Jimenez R, O'Valle F, et al. (2002) Protective effects of the flavonoid quercetin in chronic nitric oxide deficient rats. J Hypertens 20, 1843-1854.
33. Belik J, Gonzalez-Luis GE, Perez-Vizcaino F, et al. (2010) Isoprostanes in fetal and neonatal health and disease. Free Radic Biol Med 48, 177-188.
34. van Acker SA, van den Berg DJ, Tromp MN, et al. (1996) Structural aspects of antioxidant activity of flavonoids. Free Radic Biol Med 20, 331-342. (Pubitemid 26077855)
35. Kumar N, Kant R & Maurya PK (2010) Concentration-dependent effect of (2)-epicatechin in hypertensive patients. Phytother Res 24, 1433-1436.
36. Sanchez M, Galisteo M, Vera R, et al. (2006) Quercetin downregulates NADPH oxidase, increases eNOS activity and prevents endothelial dysfunction in spontaneously hypertensive rats. J Hypertens 24, 75-84. (Pubitemid 41818091)
37. Gonzalez W, Fontaine V, Pueyo ME, et al. (2000) Molecular plasticity of vascular wall during N(G)-nitro-L-arginine methyl ester-induced hypertension: modulation of proin-flammatory signals. Hypertension 36, 103-109. (Pubitemid 30602160)
38. Nicoletti A & Michel JB (1999) Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res 41, 532-543. (Pubitemid 29130617)
39. Brand K, Page S, Walli AK, et al. (1997) Role of nuclear factor-kappa B in atherogenesis. Exp Physiol 82, 297-304.
40. Hernandez-Presa M, Bustos C, Ortego M, et al. (1997) Angiotensin- converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95, 1532-1541. (Pubitemid 27142812)